Hafnium oxide nanoparticles for radiotherapy (NBTXR3)
NBTXR3 is a liquid of hafnium oxide nanoparticles injected once into a tumor before radiotherapy. When the radiation hits, the particles boost its tumor-killing effect inside the tumor.
Nanobiotix, 24 Sept 2026How far from your life: You can get it now, though it may not be common yet.
Company-reportedFrom lab to your life
Why it’s on step 4
- 1Lab discovery
- 2Working prototype
- 3Real-world testing
- 4Approved or on sale
- 5Everyday life
The rule
A regulator approved or cleared it where approval applies (the FDA, the EMA, a CE mark), or it is sold to the public or to customers beyond a trial.
- Nanobiotix said its product, sold under the name Hensify, won a CE mark in Europe for locally advanced soft tissue sarcoma. Nanobiotix via BioSpace, 4 Apr 2019
The short version
What you need to know
- Why it matters
Nanobiotix says the particles magnify the X-ray dose inside the tumor while the dose passing through healthy tissue stays the same.
Nanobiotix via BioSpace, 4 Apr 2019- Is it really nano?
Truly nano
The nanoparticles are the treatment: crystals of hafnium oxide that react to the radiation inside the tumor.
Nanobiotix via BioSpace, 4 Apr 2019- Where you’ll find it
In clinical trials, including a global phase 3 trial in head and neck cancer now run by Johnson & Johnson.
Nanobiotix, 24 Sept 2026- Who’s behind it
Nanobiotix, licensed to Johnson & Johnson in 2023
On the record
Every step, dated
Newest first. Company-reported means the only source so far is the company itself.
- Human trialCompany-reported
Nanobiotix reported that the FDA had cleared changes to the Johnson & Johnson-led phase 3 trial in head and neck cancer, NANORAY-312, so that its final analysis can come sooner.
Nanobiotix, 24 Sept 2026 - Funding or dealCompany-reported
Nanobiotix licensed NBTXR3 to Janssen, a Johnson & Johnson company, for development and sale worldwide.
Nanobiotix, 24 Sept 2026 - ApprovalCompany-reported
Nanobiotix said its product, sold under the name Hensify, won a CE mark in Europe for locally advanced soft tissue sarcoma.
Nanobiotix via BioSpace, 4 Apr 2019
Who makes it
The companies
- NBTXNasdaqNanobiotixPure play
Develops NBTXR3, hafnium oxide nanoparticles injected into tumors to boost radiotherapy, now licensed to Johnson & Johnson.
We track:NBTXR3
- JNJNYSEJohnson & Johnson
Leads the global phase 3 trial of NBTXR3, the radiotherapy-boosting nanoparticles it licensed from Nanobiotix.
We track:NBTXR3
Sources
Where every line comes from
Each source with the passage, word for word, that backs what we wrote.
- Nanobiotix, 24 Sept 2026
nanoparticles administered via one-time intratumoral injection and activated by radiotherapy.
- Nanobiotix via BioSpace, 4 Apr 2019
The dose of X-ray delivered to the tumor is magnified, whilst the dose passing through healthy tissues remains unchanged.
More in Medicine and health
- Gold nanoparticle rapid testsStep 5 · EverydayHome pregnancy tests and COVID-19 rapid tests are lateral flow tests: the sample soaks along a strip.
- mRNA vaccines in lipid nanoparticlesStep 5 · EverydayThe COVID-19 vaccines from Pfizer-BioNTech and Moderna carry messenger RNA, instructions that get cells to make a copy of one virus protein so the immune system learns to recognize it.
- Albumin-bound paclitaxel (Abraxane)Step 4 · On saleAbraxane is the cancer drug paclitaxel bound to albumin, a human blood protein, in the form of nanoparticles.
- Ferumoxytol (Feraheme)Step 4 · On saleFeraheme is an iron replacement given into a vein to adults with iron deficiency anemia.